red virus depth of field background copy space text overlay corona coronavirus corona virus disease t20 omwLB8


COVID-19 Update | March 23, 2021



COVID-19 Update


  • COVID-19
  • Disease Management


coronavirus COVID-19

This report from the Missouri Hospital Association is designed to help you stay abreast of recent developments related to COVID-19.

Share our online form with individuals interested in receiving this update.

Past issues are available in the Media Library.

Dashboard Spotlight


Herd Immunity Or A New Normal?

Staff Contact: Mat Reidhead or Jackie Gatz

A new debate is emerging in the scientific community on whether herd immunity against COVID-19 is achievable, or whether a new normal of living with the virus is more likely. Herd immunity refers to the concept in virology where the portion of the population having protection — induced from vaccination or previous infection — is large enough to prevent transmission of the disease. Unfortunately, the novel SARS-CoV-2 coronavirus and its vaccines are so novel that data supporting the possibility of herd immunity are clouded in uncertainty. For starters, estimates on the portion of the population needing protection range widely from 60% to 85%. Furthermore, due to large rates of asymptomatic cases, no one knows what the actual infection rate is, although the Centers for Disease Control and Prevention estimates it to be 4.6 times the known infection rate in the U.S. Additionally, the duration of seropositive protection is unknown, as is the efficacy of the vaccines against emerging variants. Other significant barriers underly the fact that the vaccines are not currently approved for children who make up one-fifth of the population and unanticipated sources of vaccine hesitancy — particularly along political lines — are becoming manifest.

Considering these unknowns, it is important to emphasize the words “crude estimates” in the following analysis designed to project possible dates when the critical mass of Missourians with either form of protection will converge with estimates required to induce herd immunity. Inputs include known rates of infection, CDC estimates of latent infections and known rates of vaccine series completion by Missouri residents. By March 21, 9.3% of Missouri’s total population had tested positive with diagnostic or antigen tests — using CDC estimates on unreported cases suggests the true disease burden to be 42.8% of Missourians with potential seropositive protection. On the same date, 690,000 Missourians (11.2% of the population) had completed the vaccine series. Assuming the same portion of the population with protection from a previous infection sought out the vaccines infers that 6.4% of the population has vaccine-induced protection without seropositivity from a previous infection. Using the average daily percent change in known infections and vaccine series completion between Feb. 1 and Mar. 21, 2021, to impose linear projections on the data suggests that 65% of Missourians will have some form of protection against COVID-19 by July 6. Following recent linear trends, the analysis suggests the mid-level estimate required for herd immunity of 75% would be reached by Sept. 22, and 85% of the population would have some form of protection by Dec. 22. While it is important to have targeted dates to anticipate, it also is important to understand that any one of the myriad assumptions underlying this analysis are subject to change — for example, another surge in cases, or vaccine demand becoming more anemic would significantly alter convergence dates.

MHA and HIDI will continue to monitor the data and update these projections and underlying modeling accordingly. It is critically important that Missourians continue to stave off complacency with continued masking, physical distancing and hand hygiene in addition to becoming vaccinated when eligible.

Crude Estimates of Herd Immunity Achievement in Missouri
Vaccine Updates
Government Action
Rural Resources
Testing, Reporting & Treatment
Back to Top